All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
The role of clostridium difficile infection in gastrointestinal graft-versus-host disease
Divaya Bhutani from Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA, and colleagues retrospectively analyzed the relationship between clostridium difficile infection (CDI) and acute gastrointestinal graft-versus-host disease (GI GvHD) in patients undergoing allogeneic stem cell transplantation (allo-SCT). The study was published ahead of print in Bone Marrow Transplantation.
In this study, 310 consecutive patients were included and divided into two groups:
- Group 1: n = 100 patients who received related donor allo-SCT, transplanted between March 2010 and December 2013
- Age at transplant: 54 years (range, 19–59)
- Diagnosis: leukemia (48%), lymphoma (29%), MDS (12%), other (11%)
- Source of stem cells: BM (9%), PBSC (91%)
- Group 2: n = 210 patients who received unrelated donor allo-SCT, transplanted between December 2009 and December 2013
- Age at transplant: 56 years (range, 20–62)
- Diagnosis: leukemia (57%), lymphoma (19%), MDS (14%), other (10%)
- Source of stem cells: BM (8%), PBSC (92%)
Key findings:
Data is given as group 1 vs group 2
- Cumulative incidence of CDI: 18% (95% CI, 11–26%) vs 26.7% (95% CI, 19–30%), P = 0.24
- Median time to CDI development: 12.5 days (range, Day 3 to Day 113) vs 16 days (range, Day 3 to Day 209)
- Incidence of GI GvHD: 33% vs 23%
- Use of systemic steroids: 33% vs 45%
- Median time to GvHD development: 39 days vs 28 days
- Patients with CDI were more likely developed acute GI GvHD: HR = 1.92 (95% CI, 1.15–3.19), P = 0.01
- Acute GI GvHD significantly associated with increased mortality: HR = 1.7 (95% CI, 1.15–2.5), P = 0.01
In summary, this retrospective study found that patients who develop CDI in the post-transplant period have an increased risk of acute GI GvHD. “The highest incidence of CDI is during pre-engraftment period within the first 2 weeks after transplantation, which correlates with the duration of neutropenia and antibiotic use. In addition, CDI can complicate therapy of GI GVHD with increased incidence with use of systemic steroids.”
References